{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:03Z","timestamp":1793090223110,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105597","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:59:07Z","timestamp":1789502347000},"page":"105597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies"],"prefix":"10.1016","volume":"227","author":[{"given":"Alireza","family":"Tojjari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamimeh","family":"Pourbahrighesmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Alkhazna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105597_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10476","key":"10.1016\/j.critrevonc.2026.105597_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105597_bib3","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105597_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol."},{"issue":"49","key":"10.1016\/j.critrevonc.2026.105597_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc2728","article-title":"Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding","volume":"5","author":"Andrews","year":"2020","journal-title":"Sci. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105597_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105597_bib7","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105597_bib8","first-page":"TPS3636","article-title":"OrigAMI-2: a randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS\/BRAF wild-type metastatic colorectal cancer","volume":"43","author":"Arnold","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105597_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105597_bib10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion\u2013positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105597_bib11","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105597_bib12","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105597_bib13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"New. Engl. J. Med."},{"issue":"2_","key":"10.1016\/j.critrevonc.2026.105597_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2026.44.2_suppl.166","article-title":"Amivantamab plus FOLFOX or FOLFIRI in RAS\/BRAF wild-type metastatic colorectal cancer: long-term follow-up from the phase 1b\/2 OrigAMI-1 study","volume":"44","author":"Chen","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib15","article-title":"A randomized phase 3 study of MRTX849 in combination with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRAS G12C mutation with disease progression on or after standard first-line therapy (KRYSTAL-10)","year":"2021","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.critrevonc.2026.105597_bib16","article-title":"A multicenter phase 1b\/2 study of adagrasib, cetuximab, and cemiplimab for metastatic colorectal cancer harboring KRAS G12C mutations","year":"2024","journal-title":"Clin. Gov. identifier"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105597_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105597_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105597_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105597_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105597_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAF V600E-mutant mCRC","volume":"20","author":"Elez","year":"2024","journal-title":"Future Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105597_bib22","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105597_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2025.43.4_suppl.23","article-title":"Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM)","volume":"43","author":"Fakih","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105597_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2025.43.4_suppl.127","article-title":"Zanzalintinib (XL092) alone or in combination with atezolizumab in patients with refractory metastatic colorectal cancer: results from an expansion cohort of the phase 1 STELLAR-001 study","volume":"43","author":"Fontana","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6371","key":"10.1016\/j.critrevonc.2026.105597_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105597_bib27","first-page":"TPS3638","article-title":"OrigAMI-3: a randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS\/BRAF wild-type colorectal cancer","volume":"43","author":"Hecht","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10517","key":"10.1016\/j.critrevonc.2026.105597_bib28","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105597_bib29","first-page":"LBA13","article-title":"A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC)","volume":"43","author":"Hecht","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105597_bib30","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2025.43.16_suppl.3507","article-title":"Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer","volume":"43","author":"Hollebecque","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102700","article-title":"Current advances in targeted therapy for metastatic colorectal cancer\u2013clinical translation and future directions","volume":"125","author":"Johnson","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105597_bib32","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"New. Engl. J. Med."},{"issue":"2_","key":"10.1016\/j.critrevonc.2026.105597_bib33","first-page":"TPS267","article-title":"KANDLELIT-012: phase 3 study of MK-1084 (a KRAS G12C inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for KRAS G12C-mutant colorectal cancer","volume":"44","author":"Kawazoe","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105597_bib34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"New. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105597_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib36","doi-asserted-by":"crossref","first-page":"S1688","DOI":"10.1016\/j.annonc.2025.09.040","article-title":"LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): new results from CheckMate 8HW","volume":"36","author":"Lonardi","year":"2025","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105597_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","article-title":"Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial","volume":"26","author":"Lou","year":"2025","journal-title":"Lancet Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105597_bib38","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2025.43.16_suppl.3508","article-title":"The KRAS G12C inhibitor MK-1084 for KRAS G12C\u2013mutated advanced colorectal cancer (CRC): results from KANDLELIT-001","volume":"43","author":"Lugowska","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105597_bib39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib40","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.annonc.2023.04.494","article-title":"SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the AtezoTRIBE study","volume":"34","author":"Marmorino","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.6004\/jnccn.2026.5003","article-title":"Advances in early-stage colorectal cancer care: integrating emerging evidence into practice","volume":"24","author":"Meyerhardt","year":"2026","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105597_bib42","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2026.44.16_suppl.3504","article-title":"SWOG S2107: randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF V600E metastatic colorectal cancer (mCRC)","volume":"44","author":"Morris","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105597_bib43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105597_bib44","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO-25-02187","article-title":"Amivantamab monotherapy in chemorefractory RAS\/BRAF wild-type metastatic colorectal cancer: results from OrigAMI-1, an open-label, phase Ib\/II study","volume":"44","author":"Oberstein","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105597_bib45","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105597_bib46","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105597_bib47","doi-asserted-by":"crossref","first-page":"TPS376","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS376","volume":"40","author":"Park","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105597_bib48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall survival analysis of the phase III CodeBreaK 300 study of sotorasib plus panitumumab versus investigator's choice in chemorefractory KRAS G12C colorectal cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105597_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2_","key":"10.1016\/j.critrevonc.2026.105597_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2026.44.2_suppl.14","volume":"44","author":"Rocha Lima","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105597_bib51","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105597_bib52","article-title":"Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: phase Ib CAMILLA trial results","volume":"4","author":"Saeed","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib53","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41467-024-45960-2","article-title":"Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort","volume":"15","author":"Saeed","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105597_bib54","article-title":"Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer","volume":"143","author":"Salva de Torres","year":"2026","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105597_bib55","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105597_bib56","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105597_bib57","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.annonc.2025.05.020","article-title":"8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases","volume":"36","author":"Schlechter","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib58","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105597_bib59","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","article-title":"Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer","volume":"394","author":"Sinicrope","year":"2026","journal-title":"New. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105597_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105597_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113495","article-title":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer\u2013outcome and novel predictive markers","volume":"198","author":"Stemmer","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105597_bib62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105597_bib63","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105597_bib64","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105597_bib65","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","article-title":"Molecular characterization of acquired resistance to KRASG12C\u2013EGFR inhibition in colorectal cancer","volume":"13","author":"Yaeger","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104108","article-title":"Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes","volume":"10","author":"Yamaguchi","year":"2025","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib69","article-title":"Precision oncology in colorectal cancer: integrating molecular subtyping, multidisciplinary management, and emerging therapeutics","volume":"5","author":"Yang","year":"2026","journal-title":"Clin. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105597_bib70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105597_bib71","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:57:24Z","timestamp":1793087844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":71,"alternative-id":["S1040842826004841"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105597","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105597"}}